Craig-Hallum lowered the firm’s price target on Tandem Diabetes to $35 from $50 and keeps a Buy rating on the shares. The firm notes the broad diabetes pause has continued into Q3. Revenue slightly exceeded expectations and 2023 sales guidance was lowered by -$20M due to reduced pump orders from overseas distributors caused by timing and process issues with upcoming product launches and a possible $10M reduction from a France reimbursement change regarding Control-IQ, Craig-Hallum adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TNDM:
- Tandem Diabetes price target lowered to $22 from $34 at TD Cowen
- Tandem Diabetes price target lowered to $25 from $40 at Piper Sandler
- Tandem Diabetes price target lowered to $20 from $32 at Baird
- Tandem Diabetes price target lowered to $21 from $30 at Wells Fargo
- Tandem Diabetes names Mark Novara as EVP and Chief Commercial Officer